Publications

  1. Lim MY, Al-Kali A, Ashrani AA, Begna KH, Elliott MA, Hogan WJ, Hook CC, Kaufmann SH, Letendre L, Litzow MR, Patnaik MS, Pardanani A, Tefferi A, Wolanskyj AP, Grill DE, Pruthi RK. Comparison of complication rates of Hickman((R)) catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy. Leuk Lymphoma. 2013 Jun; 54(6):1263-7. Epub 2012 Nov 19. 2310421
    View PubMed
  2. Elliott MA, Letendre L, Tefferi A, Hogan WJ, Hook C, Kaufmann SH, Pruthi RK, Pardanani A, Begna KH, Ashrani AA, Wolanskyj AP, Al-Kali A, Litzow MR. Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy. Eur J Haematol. 2012 Mar; 88(3):237-43. Epub 2011 Nov 17. 2201833
    View PubMed
  3. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011 Jul; 86(7):610-1. Epub 2011 May 31. 2167798
    View PubMed
  4. Balin SJ, Wetter DA, Kurtin PJ, Letendre L, Pittelkow MR. Myelodysplastic syndrome presenting as generalized granulomatous dermatitis. Arch Dermatol. 2011 Mar; 147(3):331-5. 2155548
    View PubMed
  5. Elliott MA, Letendre L, Gastineau DA, Winters JL, Pruthi RK, Heit JA. Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration. Eur J Haematol. 2010 Jul; 85(1):43-50. Epub 2010 Mar 20. 1992825
    View PubMed
  6. Elliott MA, Litzow MR, Letendre LL, Wolf RC, Hanson CA, Tefferi A, Tallman MS. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood. 2007 Dec 15; 110(13):4172-4. Epub 2007 Oct 01. 1867211
    View PubMed
  7. Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM, Dispenzieri A, Gertz MA, Hayman SR, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Litzow MR. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant. 2006 Jun; 37(11):1003-8. 1762821
    View PubMed
  8. Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, Tefferi A, Elliot MA, Kaufmann SH, Mesa RA, Litzow MR. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia. 2006 Jan; 20(1):29-34. 1951238
    View PubMed
  9. Litzow MR, Dietz AB, Bulur PA, Butler GW, Gastineau DA, Hoering A, Fink SR, Letendre L, Padley DJ, Paternoster SF, Tefferi A, Vuk-Pavlovic S. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. Cytotherapy. 2006; 8(3):290-8. 1769911
    View PubMed
  10. Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C. Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res. 2005 Sep 15; 11(18):6641-9. 1731956
    View PubMed
  11. Chen YC, Chou JM, Letendre L, Li CY. Clinical importance of bone marrow monocytic nodules in patients with myelodysplasia: Retrospective analysis of 21 cases. Am J Hematol. 2005 Aug; 79(4):329-31. 1729946
    View PubMed
  12. Gore SD, Smith BD, Gojo I, Grever M, Kaufmann SH, Letendre L, Leonard DGB, Marcucci G, Miller CB, Morris L, Piantadosi S, Prior T, Stock W, Karp JE. Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia. Am J Hematol. 2005 Jun; 79(2):119-27. 1720455
    View PubMed
  13. Elliott MA, Wolf RC, Hook CC, Pruthi RK, Heit JA, Letendre LL, Tefferi A, Kaufmann SH, Mesa RA, Litzow MR. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: Incidence, risk factors, and possible role of antithrombin. Leukemia & Lymphoma. 2004 Aug; 45(8):1545-9. 1649152
    View PubMed
  14. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E, Bennett JM, Rowe JM. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). J Clin Oncol. 2004 Mar 15; 22(6):1078-86. 1639652
    View PubMed
  15. Chen YC, Chou JM, Ketterling RP, Letendre L, Li CY. Histologic and immunohistochemical study of bone marrow monocytic nodules in 21 cases with myelodysplasia. Am J Clin Pathol. 2003 Dec; 120(6):874-81. 1429044
    View PubMed
  16. Litzow MR, Repoussis PD, Schroeder G, Schembri-Wismayer D, Batts KP, Anderson PM, Arndt CA, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Noel P, Solberg LA Jr, Letendre L, Hoagland HC. Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator. Leuk Lymphoma. 2002 Nov; 43(11):2099-107. 2106775
    View PubMed
  17. Hogan WJ, Letendre L, Litzow MR, Tefferi A, Hoagland HC, Pruthi RK, Kaufmann SH. Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside. Mayo Clin Proc. 2002 Aug; 77(8):760-2. 1315080
    View PubMed
  18. Porrata LF, Litzow MR, Tefferi A, Letendre L, Kumar S, Geyer SM, Markovic SN. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia. 2002 Jul; 16(7):1311-8. 1314934
    View PubMed
  19. Elliott MA, Letendre L, Hanson CA, Tefferi A, Dewald GW. The prognostic significance of trisomy 8 in patients with acute myeloid leukemia. Leuk Lymphoma. 2002 Mar; 43(3):583-6. 1316014
    View PubMed
  20. Tack DK, Letendre L, Kamath PS, Tefferi A. Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant. 2001 Nov; 28(9):895-7. 1006898
    View PubMed
  21. Steensma DP, Hanson CA, Letendre L, Tefferi A. Myelodysplasia with fibrosis: a distinct entity? Leuk Res. 2001 Oct; 25(10):829-38. 1005482
    View PubMed
  22. Greenlund LJS, Letendre L, Tefferi A. Acute leukemia during pregnancy: a single institutional experience with 17 cases. Leuk Lymphoma. 2001 May; 41(5-6):571-577. 1005350
    View PubMed
  23. Tefferi A, Elliott MA, Steensma DP, Hook CC, Dispenzieria A, Hanson CA, Schroeder G, Letendre L. Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leuk Res. 2001 Feb; 25(2):183-5. 1003355
    View PubMed
  24. Robles C, Kim KM, Oken MM, Bennett JM, Letendre L, Wiernik PH, O'Connell MJ, Cassileth PA. Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483). Leukemia. 2000 Aug; 14(8):1349-53. 1314586
    View PubMed
  25. van Der Vliet HJ, Roberson AE, Hogan MC, Morales CE, Crader SC, Letendre L, Pruthi RK. All-trans-retinoic acid-induced myositis: a description of two patients. Am J Hematol. 2000 Feb; 63(2):94-8. 127589
    View PubMed
  26. Letendre L, Noel P, White WL, Tefferi A, Litzow MR, Li CY, Schroeder G. Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C. Leuk Res. 1999 Sep; 23(9):811-5. 1008945
    View PubMed
  27. Elliott MA, Letendre L, Li CY, Hoyer JD, Hammack JE. Chronic lymphocytic leukaemia with symptomatic diffuse central nervous system infiltration responding to therapy with systemic fludarabine. Br J Haematol. 1999 Mar; 104(4):689-94. 110266
    View PubMed
  28. Mongkonsritragoon W, Letendre L, Li CY. Multiple lymphoid nodules in bone marrow have the same clonality as underlying myelodysplastic syndrome recognized with fluorescent in situ hybridization technique. Am J Hematol. 1998 Nov; 59(3):252-7. 108224
    View PubMed
  29. Mongkonsritragoon W, Letendre L, Qian J, Li CY. Nodular lesions of monocytic component in myelodysplastic syndrome. Am J Clin Pathol. 1998 Aug; 110(2):154-62. 107468
    View PubMed
  30. Letendre L, Noel P, Litzow MR, Hoagland HC, Tefferi A. Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C. Am J Clin Oncol. 1998 Apr; 21(2):142-4. 104513
    View PubMed
  31. Letendre L, Moore SB. Successful pregnancy after conditioning with cyclophosphamide and fractionated total body irradiation. Med Pediatr Oncol. 1997 Feb; 28(2):147-8. 101547
    View PubMed
  32. Kaufmann SH, Gore SD, Letendre L, Svingen PA, Kottke T, Buckwalter CA, Jones RJ, Grochow LB, Burke PJ, Donehower RC, Rowinsky EK. Factors affecting topotecan sensitivity in human leukemia samples. Ann N Y Acad Sci. 1996 Dec 13; 803:128-42. 2136088
    View PubMed
  33. Letendre L, Noel P, Tefferi A, Solberg LA Jr, Gastineau DA, Hoagland HC. Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia. Am J Clin Oncol. 1995 Oct; 18(5):382-4. 93800
    View PubMed
  34. Witzig TE, Letendre L, Gerstner J, Schroeder G, Mailliard JA, Colon-Otero G, Marschke RF, Windschitl HE. Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial. J Clin Oncol. 1995 Aug; 13(8):2012-5. 93543
    View PubMed
  35. Letendre L, Levitt R, Pierre RV, Schroeder G, Krook JA, Mailliard JE, Morton RF, Tschetter LK. Myelodysplastic syndrome treatment with danazol and cis-retinoic acid. Am J Hematol. 1995 Apr; 48(4):233-6. 92193
    View PubMed
  36. Gertz MA, Pineda AA, Chen MG, Letendre L, Greipp PR, Solberg LA Jr, Witzig TE, Garton JP, Inwards DJ, Litzow MR, et al. Refractory and relapsing multiple myeloma treated by blood stem cell transplantation. Am J Med Sci. 1995 Mar; 309(3):152-61. 2141764
    View PubMed
  37. Letendre L, Hoagland HC, Moore SB, Chen MG, Gastineau DA, Gertz MA, Habermann TM, Litzow MR, Noel P, Solberg LA Jr, et al. Mayo Clinic experience with allogeneic and syngeneic bone marrow transplantation, 1982 through 1990. Mayo Clin Proc. 1992 Feb; 67(2):109-16. 2106771
    View PubMed
  38. Afessa B, Tefferi A, Hoagland HC, Letendre L, Peters SG. Outcome of recipients of bone marrow transplants who require intensive-care unit support. Mayo Clin Proc. 1992 Feb; 67(2):117-22. 79464
    View PubMed
  39. Letendre L, Hoagland HC, Gertz MA. Hemorrhagic cystitis complicating bone marrow transplantation. Mayo Clin Proc. 1992 Feb; 67(2):128-30. 79465
    View PubMed
  40. Graham DL, Tefferi A, Letendre L, Gastineau DA, Hoagland HC, Noel P. Cytogenetic and molecular detection of residual leukemic cells after allogeneic bone marrow transplantation in chronic granulocytic leukemia. Mayo Clin Proc. 1992 Feb; 67(2):123-7. 82051
    View PubMed
  41. Brecher ME, Moore SB, Letendre L. Posttransfusion purpura: the therapeutic value of p1-a1-negative platelets. Transfusion (Paris) 1990 Jun; 30:433-435. 73484
    View PubMed
  42. Lust JA, Letendre L, Thibodeau SN. Marrow hypoplasia associated with a monoclonal CD8 large granular lymphocyte proliferation: reversal with cyclophosphamide and prednisone. Am J Med. 1989 Aug; 87(2):214-7. 69502
    View PubMed
  43. Letendre L. Treatment of lymphomatoid granulomatosis: old and new perspectives. Semin Respir Med. 1989 Apr; 10:178-181. 68932
  44. Letendre L, Niedringhaus RD, Therneau TM, Gastineau DA, Goldberg RM, Gerstner JB, Mailliard JA, Gundlach WJ, Kardinal CG, Pierre RV. Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside. Med Pediatr Oncol. 1989; 17(2):79-82. 69088
    View PubMed
  45. Diez-Martin JL, Habermann TM, Gastineau DA, Solberg LA Jr, Letendre L. Nonbacterial thrombotic endocarditis in autologous bone marrow transplantation. Am J Med. 1988 Nov; 85(5):742-4. 66792
    View PubMed
  46. Kriegshauser JS, Charboneau JW, Letendre L. Hepatic venocclusive disease after bone-marrow transplantation: diagnosis with duplex sonography. AJR Am J Roentgenol. 1988 Feb; 150(2):289-90. 64699
    View PubMed
  47. Morrison-DeLap SJ, Kuffel DG, Dewald GW, Letendre L. Unbalanced 1;7 translocation and therapy-induced hematologic disorders: a possible relationship. Am J Hematol. 1986 Jan; 21(1):39-47. 57573
    View PubMed
  48. Mailliard JA, Letendre L, Dalton RJ, Levitt R, Gerstner JB, Therneau TM, Pierre RV. Phase I-II trial of VP-16 in the treatment of acute nonlymphocytic leukemia and blast crisis of chronic granulocytic leukemia. Med Pediatr Oncol. 1986; 14(6):306-9. 59551
    View PubMed
  49. Johnson DD, Dewald GW, Pierre RV, Letendre L, Silverstein MN. Deletions of chromosome 13 in malignant hematologic disorders. Cancer Genetics & Cytogenetics. 1985 Nov; 18(3):235-41. 56018
    View PubMed
  50. Moore SB, Motschman TL, Dewald GW, Letendre L, Smithson WA, Hoagland HC. A case of unusually early but temporary humoral immune reconstitution after bone marrow transplantation. Transplantation. 1985 Jun; 39(6):675-7. 55097
    View PubMed
  51. Witzig TE, Ducatman BS, Wick MR, Letendre L, Moore SB, Ilstrup DM, Taswell HF. Platelet transfusion therapy in acute leukemia: lack of effect of splenomegaly on transfusion requirements and risk of hemorrhage. Am J Hematol. 1985 Apr; 18(4):345-50. 54492
    View PubMed
  52. Letendre L, Hinemann V, Hoagland HC, Kovach JS. Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia. Medical & Pediatric Oncology. 1985; 13(4):232-4. 55303
    View PubMed
  53. Letendre L, Ludwig J, Perrault J, Smithson WA, Kovach JS. Hepatocellular toxicity during the treatment of refractory acute leukemia with indicine N-oxide. Cancer. 1984 Oct 1; 54(7):1256-9. 52302
    View PubMed
  54. Letendre L, Kiely JM, Hoagland HC. Reinduction chemotherapy for acute nonlymphocytic leukemia. Mayo Clin Proc. 1984 Sep; 59(9):618-21. 52048
    View PubMed
  55. Vaickus L, Letendre L. Pericarditis induced by high-dose cytarabine therapy. Arch Intern Med. 1984 Sep; 144(9):1868-9. 52475
    View PubMed
  56. Letendre L, Kyle RA. Monoclonal cryoglobulinemia with high thermal insolubility. Mayo Clin Proc. 1982 Oct; 57(10):629-33. 46185
    View PubMed
  57. Letendre L, Colgan JP, Hineman VL, Hoagland HC. Treatment of adult acute lymphocytic leukemia. Mayo Clin Proc. 1982 Jul; 57(7):426-30. 45812
    View PubMed
  58. Letendre L, Banks PM, Reese DF, Miller RH, Scanlon PW, Kiely JM. Primary lymphoma of the central nervous system. Cancer. 1982 Mar 1; 49(5):939-43. 45041
    View PubMed
  59. Hoagland HC, Letendre L. Bone marrow transplantation. Mayo Clin Proc. 1981 Mar; 56:204. 42354
  60. Letendre L, Smithson WA, Gilchrist GS, Burgert EO Jr, Hoagland CH, Ames MM, Powis G, Kovach JS. Activity of indicine N-oxide in refractory acute leukemia. Cancer. 1981 Feb 1; 47(3):437-41. 42359
    View PubMed
  61. Edmonson JH, Frytak S, Letendre L, Kvols LK, Eagan RT. Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):2081-3. 38785
    View PubMed